Aprepitant |
|
Synonyms: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; Emend; L 754030; MK 0869; MK 869; ONO 7436; | |
Cat. No.: A66200 | CAS No.: 170729-80-3 |
MDL.: | Formula: C23H21F7N4O3 |
F.W.534.43 | Purity: 99% |
Storage: -20°C Freezer | |
  |

Catalog Number: | A66200 | CAS No.: | 170729-80-3 | |
MDL: | Formula: | C23H21F7N4O3 | ||
F.W.: | 534.43 | Purity: | 99% | |
Package: | Unit: | mg | ||
Appearance: | White to Off-White Solid | M.P.: | 244-246°C | |
B.P.: | Density: | |||
Optical Rotation: | Refractive Index: | |||
Solubility: | Stability: | Chloroform, Methanol | ||
Storage: | -20°C Freezer | Category: | Reference Standard | |
Reference: | Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998), Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001), Van Belle, S., et al.: Cancer, 94, 3032 (2002), Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006), | |||
Application: | A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic. | |||
Category: | Chiral Reagents, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, |